loader2
Partner With Us NRI

Ipca Laboratories Ltd share Price Today

Company details

1,206.05
1,237.00
775.05
1,374.60
6M Return 9.13%
1Y Return 61.34%
Mkt Cap.(Cr) 30,906.22
Volume 375,405
Div Yield 0.16%
OI
-
OI Chg %
-
Volume 375,405

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Technical Outlook
    Nifty Pharma index has been in corrective phase since October 2021 undergoing significant price/time correction. Over past couple of weeks index has witnessed renewed buying interest and formed potential Bullish Morning star reversal pattern on Monthly time frame. We expect sector to outperform in coming months
     
    Ipca Laboratories share price offers favourable risk-reward setup ahead of its quarterly earnings  as it is poised near 80% retracement of post COVID rally (600-1383)
     
    Key observations that support our bullish stance:
    Share price formed potential bullish reversal candlestick pattern on monthly chart at key support of ₹770  as it is sustaining above previous month high for first time in six months
     
    In the month of March, share price bounced from lower band of key trendline connecting major swing lows over past one year
     
    We expect share price to rally towards ₹950 over next few months as it is monthly highs of October and November 2022 and breakdown level in June 2022
Fundamental Outlook
    Ipca is a pharma company manufacturing over 350 formulations and 80 APIs. Major therapeutic segments include pain management, cardiovascular and anti-diabetics, anti-infectives, anti-malarials, which together account for 75% of revenues.
     
    According to IQVIA, MAT sales of IPCA for Q4FY23 grew ~20% YoY , whereas IPM grew 15% for the same.

     We expect IPCA revenue to grow at ~10% CAGR (FY23E-25E) on the back of Incremental growth in other therapies (excluding malaria), especially non-communicable diseases like pain management, cardio-diabetology.

     Sustained traction from branded and generics exports sales with a revival in the EU likely to mitigate the US void. Better offtake and market gains in export of Sartan APIs remains key monitorable going forward .On this basis, we expect EBITDA of IPCA to grow at 26% CAGR (FY23E-25E)

     We expect commissioning of Devas plant and additional capacities from Ratlam plant can have positive implications.

     Ipca remains a decent player with a judicious mix of strong domestic franchise and a spread-out exports model with healthy balance sheet. That said, we believe progress on the margins front is likely to weigh on sentiments

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Ipca Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Standalone Net total Income up 6% at Rs 1,525.72 crore.
  • Consolidated Net total Income up 33% at Rs 2,051.93 crore.
  • Indian formulations income up 13% at Rs 689.83 crore.
  • Exports Income up 7% at Rs 731.38 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.50% in Q4 FY24 as against @ 11.75% in Q4 FY23.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items).@ 14.98% in Q4 FY24 as against @11.29% in Q4 FY23.
  • Standalone Net Profit at Rs 64.76 crore (after exceptional items) down 24%.
  • Consolidated Net Profit at Rs 59.59 crore (after exceptional items) down 22%.
  • The Board has recommended final dividend of Rs 2/- per share (200%)

FY24 Financial Highlights:

  • Standalone Net Total Income up 6% at Rs 6,111 crore.
  • Consolidated Net Total Income up 23% at Rs 7,829.81 crore.
  • Indian formulations income up 12% at Rs 3,097.16 crore.
  • Exports Income up 2% at Rs 2,707.70 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 19.29% in FY24 as against @ 16.22% in FY23
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 16.72% in FY24 as against @ 15.35% in FY23
  • Standalone Net Profit at Rs 530.41 crore (after exceptional items) up 5%.
  • Consolidated Net Profit at Rs 547.35 crore (after exceptional items) up 16%

Result PDF

View Other Company Results

Ipca Laboratories Ltd shares SWOT Analysis

Strengths (4)

  • Company with Low Debt
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge

Weakness (3)

  • MFs decreased their shareholding last quarter
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 1,234.8
R2 1,251.4
R3 1,265.7
Pivot

1,220.42

S1 1,203.8
S2 1,189.5
S3 1,172.9
EMA SMA
1,189.8
1,202.0
1,198.3
1,141.1
1,163.3
1,212.6
1,231.3
1,149.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 867.55 158841 NSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-11-14 867.55 158841 NSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-03 927.15 158842 NSE
Name Category Shares
Usha M Chandurkar PROMOTER 3.27%
Premchand Godha PROMOTER 2.29%
Usha Premchand Godha PROMOTER 0.95%
Sameer M Chandurkar PROMOTER 0.79%
Pranay Godha PROMOTER 0.67%
Prashant Godha PROMOTER 0.62%
Kaygee Investments Private Limited PROMOTER 21.47%
Kaygee Laboratories Private Limited PROMOTER 6.61%
Chandurkar Investments Private Limited PROMOTER 5.5%
Paschim Chemicals Pvt Ltd PROMOTER 4.01%

OUR RESEARCH VIEW

Investment recommendation
Call Date
20 Apr 2023
Entry Price 815.00
Target Price 940.00
Duration
3 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Ipca Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Ipca Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,218.20 1,579.30 1,510.40 4,570.80 1,184.80
% Change -0.66 -1.20 -0.19 -1.43 0.39
Mcap Cr 30,906.22 378,926.98 121,944.71 121,340.57 119,218.60
Revenue TTM Cr 6,244.32 48,496.85 15,790.60 7,665.00 19,547.40
Net Profit TTM Cr 491.93 9,648.44 2,513.47 1,576.00 3,854.40
PE TTM 50.25 37.93 28.66 75.74 30.89
1 Year Return 61.34 51.13 48.56 25.57 103.71
ROCE 11.59 17.20 14.76 16.27 23.94
ROE 8.70 16.13 10.66 12.04 20.64
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 5,842.02 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,424.68 50,451.86
LAST 3M 101,404.97 51,097.20
LAST 6M 186,293.66 40,305.54
LAST 12M 309,547.75 87,515.42
IPCA Laboratories Limited - Credit Rating

Jul 16, 2024 l NSE Announcement

IPCA Laboratories Limited - Change in Director

Jul 12, 2024 l NSE Announcement

IPCA Laboratories Limited - Updates

Jul 11, 2024 l NSE Announcement

Date Action Type Ratio
Nov 22, 2023 Dividend 200
Nov 22, 2022 Dividend 400
Jan 10, 2022 Split 1:2

Ipca Laboratories Ltd Information

Stock PE (TTM)
50.25
Promoter Holding
46.3%
Book Value
249.5895
ROCE
11.59%
ROE
8.7%
Description
  • Ipca Laboratories Ltd is a pharmaceutical company based in India. On October 19, 1949, the company was incorporated in Mumbai under the name The Indian Pharmaceutical Combine Association Limited. The company was named Ipca laboratories Ltd in 1964, and then it was changed to Ipca Laboratories Private Limited. However, in 1988, it was again changed back to Ipca Laboratories Ltd.

    Ipca laboratories Ltd is listed on the Bombay Stock Exchange with the code 524494 and on the National Stock Exchange with the symbol IPCALAB. The company had a market capitalisation of Rs 22,016 crore on November 18, 2022.

    Ipca Laboratories Ltd manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). It has 17 manufacturing units across India, and its products are exported to 100 countries. Some APIs that Ipca Laboratories Ltd manufactures are Atenolol, Chloroquine phosphate, Chlorthalidone, Furosemide, and Hydroxychloroquine sulfate. The company has introduced a number of medicine brands, such as Zerodo, Perinorm, Tenoric, Lumerax, and Folitrax, to name a few. The subsidiary companies of Ipca laboratories Ltd are Ipca Pharmaceuticals Inc, Ipca laboratories (UK) Ltd, and Tonira Exports Ltd.

    On November 17, 2022, Ipca Laboratories Ltd’s share price closed at Rs 867.80. The share prices of Ipca laboratories Ltd have risen by 52.29% over the past three years and fallen by 16.63% in the past 12 months. The share’s 52-week high was Rs 1,128.50, and the 52-week low was Rs 831.05 as of November 18, 2022.

    In the third quarter of 2022, the company’s revenue was Rs 1,601 crore, which is 0.95% more than the previous quarter. The company had the best quarter in September 2021, with a profit of Rs 250 crore. The profit in the September quarter of 2022 was Rs 144 crore.

    As of November 18, 2022, 46.29% of Ipca Laboratories Ltd’s shares are owned by the promoters, followed by mutual funds and foreign institutional investors with 29.71% and 10.55% company shares, respectively.

    Premchand Godha is the chairman and managing director of the company, Ajit Kumar Jain is the joint managing director, and Pranay Godha and Prashant Godha are executive directors.        

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067

Tel : 91-22-66474444
Email : investors:ipca.com ; ipca:ipca.com
Website : http://www.ipca.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524494
NSE Code : IPCALAB
Book Closure Date (Month) :
BSE Group : A
ISIN : INE571A01038

FAQ’s on Ipca Laboratories Ltd Shares

You can buy Ipca Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ipca Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 16, 2024 03:58 PM the closing price of Ipca Laboratories Ltd was Rs.1,218.20.

The latest PE ratio of Ipca Laboratories Ltd as of Jul 16, 2024 03:58 PM is 50.25

The latest PB ratio of Ipca Laboratories Ltd as of Jul 16, 2024 03:58 PM is 0.20

The 52-week high of Ipca Laboratories Ltd share price is Rs. 1,374.60 while the 52-week low is Rs. 775.05

According to analyst recommendations, Ipca Laboratories Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 16, 2024 03:58 PM, the market cap of Ipca Laboratories Ltd stood at Rs. 30,906.22 Cr.

Download App

Download Our App

Play Store App Store
market app